Strategic Partnership Aims to Make Advanced Cancer Therapy Accessible in China

Introduction to the Partnership

Shanghai Grit Biotechnology Co., Ltd. (GRIT) and Shandong Quangang Pharmaceutical Co., Ltd. (Quangang) have joined forces to drive innovation in T-cell therapy. This strategic partnership aims to develop a globally standardized Interleukin-2 (IL-2) for Chinese cancer patients, making it more accessible and affordable.

Objectives of the Collaboration

The collaboration's primary objective is to expand the use of Quanqi (125SER) Interleukin-2 (IL-2) for treating various solid tumors. IL-2 is a critical immune-regulating cytokine that aids in the treatment of cancers like renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, colorectal cancer, lymphoma, and lung cancer.

The goal is to localize this global standard IL-2 product, ensuring it meets the needs of Chinese patients by making it more accessible and affordably priced.

About GRIT and Quangang

GRIT is a clinical-stage cell therapy company focusing on tumor infiltrating lymphocytes (TILs) therapy. Their non-gene-engineered TIL program, GT101, is currently in Phase 2 clinical trials, marking the fastest TIL development pipeline in China with goals for a Biologics License Application (BLA) in 2025.

Quangang Pharmaceutical is a leading biopharmaceutical company in China, renowned for its expertise in genetic medicine research. The company is well-equipped with GMP facilities and advanced biotechnology research capabilities.

Significance for Chinese Cancer Patients

Through this partnership, GRIT aims to leverage its vast experience in T-cell therapy to quicken the advancement and commercialization of innovative cell therapy products. This initiative will broaden treatment options and offer new hope to Chinese solid tumor patients.

The joint efforts from both companies are expected to provide Chinese cancer patients with early access to advanced T-cell therapy options that are effective and cost-efficient, significantly improving their treatment experiences.

Future Prospects

The outcomes of this strategic collaboration could potentially set new benchmarks in the Chinese oncology landscape. By ensuring the local availability of this immune-boosting IL-2 therapy, the partnership aims to address substantial unmet medical needs among cancer patients in China.

The success of this initiative could lead to further advancements in the field of cancer immunotherapy, offering promising prospects for both GRIT and Quangang in the Chinese biotech industry.

Conclusion

This partnership between GRIT and Quangang represents a significant step towards making cutting-edge cancer treatments accessible to those who need them most. By bringing together their expertise, the companies hope to serve a broader spectrum of Chinese patients with advanced T-cell therapy at accessible prices.